Prevacid Related Published Studies
Well-designed clinical trials related to Prevacid (Lansoprazole)
A multicenter, randomized, comparative study to determine the appropriate dose of lansoprazole for use in the diagnostic test for gastroesophageal reflux disease. [2011.09]
Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. [2011.07]
Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. [2011.06]
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. [2011.03]
The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease. [2011.02]
Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection. [2011]
Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. [2010.12]
Dilated intercellular space in chronic laryngitis and gastro-oesophageal reflux disease: at baseline and post-lansoprazole therapy. [2010.10]
Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients. [2010.10]
Mosapride as an adjunct to lansoprazole for symptom relief of reflux oesophagitis. [2010.08]
Clinical trial: chest pain caused by presumed gastro-oesophageal reflux in coronary artery disease - controlled study of lansoprazole vs. placebo. [2010.07]
Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole. [2010.07]
Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. [2010.07]
Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole. [2010.05]
The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor. [2010.05]
Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors. [2010.04]
Patient self-treatment using lansoprazole for frequent nighttime heartburn. Commentary. [2010.01]
Does pretreatment with lansoprazole influence Helicobacter pylori eradication rate and quality of life? [2010]
Clinical trial: chest pain caused by presumed gastro-oesophageal reflux in
coronary artery disease - controlled study of lansoprazole vs. placebo. [2010]
Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric
acid: a comparison of over-the-counter doses of proton pump inhibitors. [2010]
Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants. [2009.12]
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. [2009.11.15]
Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. [2009.11.01]
[Evaluation of preferences in patients with gastroesophageal reflux disease and dysphagia concerning treatment with lansoprazole orally disintegrating tablets.] [2009.10]
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. [2009.09.04]
Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects. [2009.09.01]
A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. [2009.08]
Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis. [2009.08]
Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole. [2009.07.01]
Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. [2009.07]
The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. [2009.06.15]
Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine. [2009.05]
Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? [2009.05]
Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility. [2009.04.15]
Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. [2009.04.01]
Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies. [2009.04.01]
Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. [2009.04]
Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. [2009.04]
Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH. [2009.03]
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. [2009.02.28]
Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Assessing the Efficacy and Safety of Proton Pump Inhibitor Lansoprazole in Infants with Symptoms of Gastroesophageal Reflux Disease. [2008.12.01]
Lansoprazole in globus pharyngeus: double-blind, randomized, placebo-controlled trial. [2008.10]
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. [2008.04]
Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. [2008.03]
Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: a randomized controlled trial with 12-month follow-up. [2007.07]
Acid control with esomeprazole and lansoprazole: a comparative dose-response study. [2007.02]
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. [2006.10]
A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. [2006.07]
Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. [2006.07]
Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve. [2006.06]
Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. [2006.04.15]
Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages. [2006.04.01]
Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. [2006.04.01]
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. [2006.02.01]
Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. [2006.02]
Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: A comparison between two different daily doses of lansoprazole. [2006.01.07]
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole. [2006.01]
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. [2006.01]
Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. [2006]
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. [2005.11]
Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. [2005.10.01]
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. [2005.09]
A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. [2005.07.15]
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. [2005.07.01]
Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry. [2005.07]
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. [2005.07]
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. [2005.06]
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. [2005.06]
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. [2005.05]
Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole based triple therapy: an open randomized clinical trial. [2005.04]
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. [2005.03]
Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. [2005.02.15]
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. [2004.12]
Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. [2004.12]
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. [2004.11]
Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. [2004.10.15]
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. [2004.10]
Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. [2004.09.15]
A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube. [2004.08.15]
Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. [2004.07.31]
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. [2004.07.01]
A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. [2004.06.01]
Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. [2004.06.01]
The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. [2004.05.15]
Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole. [2004.05.15]
Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. [2004.02.15]
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. [2003.12]
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. [2003.12]
Nutcracker oesophagus: a double-blind, placebo-controlled, cross-over study of the effects of lansoprazole. [2003.12]
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. [2003.10.15]
Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. [2003.09]
Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. [2003.04]
Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. [2003.03.15]
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. [2003.02]
Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis. [2003.02]
Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. [2003.02]
Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. [2003.02]
Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection. [2003.02]
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. [2003.01]
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. [2003.01]
Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. [2003]
|
